Research information only, not medical advice. Research peptide, not approved for human use anywhere. Up for an FDA advisory committee vote on July 23, 2026 (evaluated indication: Wound healing and inflammatory conditions). Removed from the FDA 'do not compound' list in April 2026 but not yet compoundable.
KPV at a glance
As of June 2026 the human evidence is limited; most data is preclinical. See the indexed studies below, graded by evidence level.
The peptides on the agenda are covered in the July 2026 FDA peptide meeting .
Evidence profile
65 studies- Human trial 1 · 2%
- Review 8 · 12%
- Animal 14 · 22%
- In-vitro 20 · 31%
- Unknown 22 · 34%
The longer the green, the stronger the human evidence. For most research peptides the bar is dominated by animal and in-vitro work, which is a signal to read every claim carefully.
Regulatory status
- 2026-04-22 US-FDA
Removed from the FDA 503A 'do not compound' Category 2 (nominations withdrawn) — still not eligible for compounding. source
- 2026-07-23 US-FDA · upcoming
FDA Pharmacy Compounding Advisory Committee vote (evaluated indication: Wound healing and inflammatory conditions); docket FDA-2025-N-6895. source
Indexed research
Sorted by evidence level, strongest first.
- Human trial 2026Project Title:"A 3-Month Pilot Pre-Trial of a Multi-Peptide Protocol (BPC-157/KPV/GHK-Cu Blend + TB-500 + Ara290 + Semax) for Arthritis, Cartilage Repair, Neuropathic Pain, and Mobility in Older Adults
This pilot pre-trial investigates a multi-peptide protocol in older adults for arthritis, cartilage repair, neuropathic pain, and mobility over 3 months.
- Review 2026A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review
This critical review examines the limited clinical evidence and potential risks of peptide and peptide-analog drugs used for performance enhancement in sport and bodybuilding.
- Review 2025Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease
- Review 2025Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review
- Review 2026REGENERATIVE PEPTIDES IN MUSCULOSKELETAL MEDICINE: COMPARATIVE MECHANISMS OF BPC-157, THYMOSIN BETA-4/TB-500, TB-500 FRAGMENT AND KPV IN OSTEOMYOARTICULAR REPAIR
This integrative review analyzes the biological mechanisms and translational potential of BPC-157, Thymosin Beta-4, TB-500, TB-500 Fragment, and KPV in musculoskeletal regeneration, concluding that while findings are promising, further controlled clinical trials are needed.
- Review 2026How effective is KPV in the treatment of MCAS?
This article found no direct evidence for KPV in treating MCAS, with only indirect studies suggesting potential anti-inflammatory effects in other conditions.
- Review 2026How effective is KPV in the treatment of MCAS?
This article finds no direct evidence for KPV in treating MCAS and notes indirect anti-inflammatory effects that require further research.
- Review 2026Precision Micro-Peptides for Autoimmune and Barrier Organ Repair: Mechanistic Comparison and Synergy of KPV, BPC-157, and TB-500
This project description synthesizes existing preclinical and mechanistic evidence on KPV, BPC-157, and TB-500 to propose a comparative synergy model and an experimental blueprint for future testing.
- Review 2025Recalibrating Retinal Immunity: Peptide-Based Strategies for Durable Vision Preservation in Retinitis Pigmentosa
This article reviews peptide-based immunomodulatory and regenerative immunotherapy strategies, including AASI, stem cell combinations, and delivery advances, for preserving vision in retinitis pigmentosa, while noting that clinical translation remains limited by manufacturing, regulatory, safety, and trial-design challenges.
- Animal 2026NLRP3 autophagic degradation disruption in melanocytes contributes to vitiligo development
+ 55 more studies indexed for KPV.
Frequently asked questions
- Is KPV approved for human use?
- Research peptide, not approved for human use anywhere. Up for an FDA advisory committee vote on July 23, 2026 (evaluated indication: Wound healing and inflammatory conditions). Removed from the FDA 'do not compound' list in April 2026 but not yet compoundable.
- What does the research on KPV show?
- As of June 2026 the human evidence is limited; most data is preclinical. See the indexed studies below, graded by evidence level.